Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic.
Coronavirus disease 2019
DMARDs (biologic)
JAK inhibitors
cytokine
disease modifying anti-rheumatic drug
immunesuppressants
severe acute respiratory syndrome coronavirus 2
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
08
2020
accepted:
17
11
2020
entrez:
14
1
2021
pubmed:
15
1
2021
medline:
15
1
2021
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) is a condition caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Severe cases of COVID-19 result in acute respiratory distress syndrome and death. A detrimental, hyper-inflammatory immune response with excess release of cytokines is the main driver of disease development and of tissue damage in these patients. Thus, repurposing of biologic agents and other pharmacological inhibitors of cytokines used for the treatment of various inflammatory conditions emerged as a logical therapeutic strategy to quench inflammation and improve the clinical outcome of COVID-19 patients. Evaluated agents include the interleukin one receptor blocker anakinra, monoclonal antibodies inhibiting IL-6 tocilizumab and sarilumab, monoclonal antibodies inhibiting granulocyte-monocyte colony stimulating factor and tumor necrosis factor, and Janus kinase inhibitors. In this review, we discuss the efficacy and safety of these therapeutic options based on direct personal experience and on published evidence from observational studies and randomized clinical trials.
Identifiants
pubmed: 33442386
doi: 10.3389/fphar.2020.598308
pii: 598308
pmc: PMC7798432
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
598308Informations de copyright
Copyright © 2020 Cavalli, Farina, Campochiaro, De Luca, Della-Torre, Tomelleri and Dagna.
Déclaration de conflit d'intérêts
GC received consultation honoraria from Amgen, Cerecor, Pfizer, Roche, Novartis and SOBI outside of the current work. CC received consultation honoraria from Roche and SOBI outside of the current work. GL received consultation honoraria from SOBI, Novartis, Pfizer, Celgene, Merck, and Roche outside of the current work. LD received consultation honoraria from Abbvie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, GlaxoSmithKline, Novartis, Pfizer, Roche, Sanofi-Genzyme, and SOBI outside of the current work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. ;377(19):1904
pubmed: 29120142
Drugs. 2019 Nov;79(16):1741-1755
pubmed: 31486005
Oncoimmunology. 2017 Apr 20;6(6):e1318237
pubmed: 28680751
Autoimmun Rev. 2015 Apr;14(4):352-7
pubmed: 25528219
Eur J Intern Med. 2020 Jun;76:21-22
pubmed: 32425364
Cell Commun Signal. 2017 Jun 21;15(1):23
pubmed: 28637459
Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1357-62
pubmed: 26787886
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
Drugs. 2020 Sep;80(13):1267-1292
pubmed: 32696108
Front Immunol. 2019 Sep 04;10:2055
pubmed: 31552022
Crit Care Resusc. 2020 Sep;22(3):200-211
pubmed: 32900326
Mediators Inflamm. 2015;2015:568543
pubmed: 25838639
J Mol Biol. 2020 Apr 3;432(8):2525-2545
pubmed: 31972172
Front Med (Lausanne). 2020 Feb 21;7:42
pubmed: 32154255
Ann Rheum Dis. 2020 Apr;79(4):536-544
pubmed: 32114511
Eur J Intern Med. 2020 Jun;76:36-42
pubmed: 32448770
J Med Virol. 2020 Oct;92(10):1787-1788
pubmed: 32297987
Front Immunol. 2020 Jun 16;11:1446
pubmed: 32612617
Cytokine. 2018 Apr;104:8-13
pubmed: 29414327
Oncologist. 2018 Aug;23(8):943-947
pubmed: 29622697
Lancet Rheumatol. 2020 Aug;2(8):e457-ee458
pubmed: 32835251
Lancet. 2020 Feb 15;395(10223):e30-e31
pubmed: 32032529
J Allergy Clin Immunol. 2020 Jul;146(1):137-146.e3
pubmed: 32470486
Pharmacotherapy. 2020 Aug;40(8):843-856
pubmed: 32542785
Lancet. 2020 May 2;395(10234):1407-1409
pubmed: 32278362
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Pacing Clin Electrophysiol. 2020 Aug;43(8):891-893
pubmed: 32543745
J Med Virol. 2020 Jul;92(7):814-818
pubmed: 32253759
Bioorg Med Chem. 2020 Mar 1;28(5):115327
pubmed: 31992476
Ann Rheum Dis. 2017 May;76(5):840-847
pubmed: 27856432
N Engl J Med. 2017 Jul 27;377(4):317-328
pubmed: 28745999
Lancet Rheumatol. 2020 Oct;2(10):e603-e612
pubmed: 32838323
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Ann Rheum Dis. 2020 Oct;79(10):1381-1382
pubmed: 32376597
Clin Exp Rheumatol. 2020 May-Jun;38(3):529-532
pubmed: 32359035
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942
pubmed: 32301997
Pharmacol Res. 2020 Nov;161:105114
pubmed: 32758635
J Immunol. 2017 Feb 15;198(4):1395-1402
pubmed: 28167650
Autoimmun Rev. 2020 Jul;19(7):102573
pubmed: 32387470
Semin Arthritis Rheum. 2021 Feb;51(1):1-6
pubmed: 33340821
J Infect. 2020 Oct;81(4):647-679
pubmed: 32592703
Expert Opin Drug Saf. 2020 Dec;19(12):1549-1558
pubmed: 33078630
Front Pharmacol. 2017 Jun 13;8:369
pubmed: 28659802
Blood. 1991 Dec 1;78(11):2918-22
pubmed: 1954380
Cell Host Microbe. 2020 Jul 8;28(1):117-123.e1
pubmed: 32411313
Am J Respir Crit Care Med. 2015 Mar 1;191(5):596-8
pubmed: 25723826
Immunotherapy. 2016 Jul;8(8):959-70
pubmed: 27381687
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Front Med. 2019 Oct;13(5):610-617
pubmed: 31571160
Front Immunol. 2020 Jul 10;11:1708
pubmed: 32754163
Ann Rheum Dis. 2011 Sep;70(9):1542-9
pubmed: 21613310
Nat Rev Rheumatol. 2016 May;12(5):259-68
pubmed: 27009539
Lancet Rheumatol. 2020 Aug;2(8):e474-e484
pubmed: 32835257
Front Immunol. 2020 Jun 23;11:1439
pubmed: 32655577
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Front Immunol. 2017 Feb 09;8:131
pubmed: 28232838
J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331
pubmed: 32171193
Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1363-8
pubmed: 26787888
Blood Purif. 2021;50(1):102-109
pubmed: 32659757
N Engl J Med. 2020 Dec 10;383(24):2333-2344
pubmed: 33085857
Front Immunol. 2018 Jun 01;9:1233
pubmed: 29910817
Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1896-903
pubmed: 11734443
Arthritis Res Ther. 2019 Feb 13;21(1):54
pubmed: 30760322
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14
pubmed: 18490652
Eur J Intern Med. 2020 Jun;76:31-35
pubmed: 32405160
J Cell Physiol. 2021 Mar;236(3):1638-1657
pubmed: 32794180
J Clin Invest. 1997 Jun 15;99(12):2930-40
pubmed: 9185517
Lancet Rheumatol. 2020 Jul;2(7):e393-e400
pubmed: 32835245
Lancet Rheumatol. 2020 Dec;2(12):e732-e734
pubmed: 33020750
Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii111-5
pubmed: 23532440
Am J Cardiol. 2015 Feb 1;115(3):288-92
pubmed: 25482680
Arthritis Rheumatol. 2020 Feb;72(2):326-334
pubmed: 31513353
Arthritis Rheumatol. 2020 Dec;72(12):1990-1997
pubmed: 32602262
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Lancet Rheumatol. 2020 Oct;2(10):e579-e580
pubmed: 32838322
Blood. 2011 Apr 7;117(14):3720-32
pubmed: 21304099
N Engl J Med. 2012 Dec 20;367(25):2385-95
pubmed: 23252525
Trends Immunol. 2002 Aug;23(8):403-8
pubmed: 12133803
J Med Virol. 2020 Nov;92(11):2283-2285
pubmed: 32343429
Crit Care Med. 2016 Feb;44(2):275-81
pubmed: 26584195
Blood. 2019 Feb 14;133(7):697-709
pubmed: 30463995
Front Pharmacol. 2018 Nov 06;9:1157
pubmed: 30459597
Arthritis Rheumatol. 2016 Mar;68(3):566-76
pubmed: 26314788
Ann Rheum Dis. 2022 Jan;81(1):e11
pubmed: 31818808
Ann Rheum Dis. 2020 Oct;79(10):1277-1285
pubmed: 32620597
J Inflamm (Lond). 2010 Aug 11;7:41
pubmed: 20701804
J Infect. 2020 Jun;80(6):639-645
pubmed: 32240670
JAMA Intern Med. 2021 Jan 1;181(1):32-40
pubmed: 33080017
Scand J Rheumatol. 2015;44(4):309-14
pubmed: 25656459
Crit Care. 2020 Jul 17;24(1):444
pubmed: 32680535
Annu Rev Immunol. 1998;16:27-55
pubmed: 9597123
Ann Intern Med. 2018 Dec 4;169(11):819-820
pubmed: 30073251
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
J Med Virol. 2020 Nov;92(11):2368-2370
pubmed: 32472703
Panminerva Med. 2022 Jun;64(2):244-252
pubmed: 33073557
J Allergy Clin Immunol. 2020 Jul;146(1):213-215
pubmed: 32437739
Int J Infect Dis. 2020 Oct;99:28-33
pubmed: 32721528
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Ann Rheum Dis. 2020 Jun;79(6):685-699
pubmed: 31969328
Rheumatology (Oxford). 2015 Dec;54(12):2134-44
pubmed: 26209330
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
Eur J Intern Med. 2020 Jun;76:43-49
pubmed: 32482597
Lancet Rheumatol. 2020 Aug;2(8):e465-e473
pubmed: 32835256
Clin Immunol. 2020 Aug;217:108509
pubmed: 32535188
Front Immunol. 2020 Jul 03;11:1625
pubmed: 32719685
Clin Exp Immunol. 2004 Apr;136(1):95-103
pubmed: 15030519
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Eur J Immunol. 2001 Sep;31(9):2566-73
pubmed: 11536154
Curr Opin Immunol. 2009 Oct;21(5):514-21
pubmed: 19796925
Annu Rev Immunol. 2009;27:519-50
pubmed: 19302047
Ann Rheum Dis. 2020 Jul 31;:
pubmed: 32737105
Lancet Rheumatol. 2020 Jun;2(6):e325-e331
pubmed: 32501454
Crit Care Med. 2016 Aug;44(8):e751-4
pubmed: 27031379